Ryosuke Arai

Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.

Yuta Tanaka, B. Saito, Kazunobu Aoyama, 2018, Bioorganic & medicinal chemistry.

DOCK2 is involved in the host genetics and biology of severe COVID-19

M. Kanai, Y. Kamatani, Y. Okada, 2022, Nature.

Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.

K. Fukuda, Y. Imaeda, Y. Kosugi, 2017, ACS medicinal chemistry letters.

Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force

M. Kanai, Y. Okada, S. Fuke, 2022, BMC infectious diseases.

Parallel fluorescent probe synthesis based on the large-scale preparation of BODIPY FL propionic acid.

M. Yoshikawa, N. Nii, Y. Tomata, 2017, Bioorganic & medicinal chemistry letters.

Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

M. Kanai, Y. Okada, S. Fuke, 2021, medRxiv.

Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

M. Kanai, Y. Okada, S. Fuke, 2023, Nature Genetics.

Potential biomarker enhancing the activity of tuberculosis, hsa-miR-346.

Naoki Miyazaki, N. Hasegawa, Y. Nakajima, 2021, Tuberculosis.